Loading...
•
Sep 30, 2021
MannKind Q3 2021 Earnings Report
Reported a 45% increase in total revenues compared to Q3 2020.
Key Takeaways
MannKind Corporation reported a total revenue of $22.2 million for Q3 2021, a 45% increase compared to Q3 2020. Afrezza net revenue increased by 34% to $9.8 million, and collaboration and services revenue increased by 54% to $12.5 million. The net loss for the quarter was $4.4 million, or $0.02 per share, compared to $11.3 million in Q3 2020.
Total revenues for Q3 2021 were $22.2 million, a 45% increase compared to Q3 2020.
Afrezza net revenue for Q3 2021 was $9.8 million, a 34% increase compared to Q3 2020.
Collaboration and services revenue for Q3 2021 increased by 54% due to additional development work with United Therapeutics.
Cash, cash equivalents, and investments totaled $181.1 million as of September 30, 2021.
Revenue by Segment
Forward Guidance
MannKind is preparing for the potential commercial launch of Tyvaso DPI, advancing its pipeline, and growing Afrezza.
Positive Outlook
- Preparing for the commercial launch of Tyvaso DPI.
- Moving the pipeline forward.
- Growing Afrezza sales.
- Completed animal toxicology studies of inhaled clofazimine.
- Aiming to move inhaled clofazimine into Phase 1 clinical trials by year-end.
Challenges Ahead
- Tyvaso DPI may not be approved by the FDA on the expected timeline, or at all.
- Risks associated with product commercialization.
- Risks associated with developing product candidates.
- Risks associated with MannKind’s ability to manage its existing cash resources or raise additional cash resources.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...